Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.

被引:12
|
作者
Sana, Talea [1 ]
Qayyum, Shaista [2 ]
Jabeen, Almas [2 ]
Siddiqui, Bina S. [1 ]
Begum, Sabira [1 ]
Siddiqui, Rafat A. [3 ]
Hadda, Taibi B. [4 ]
机构
[1] Univ Karachi, HEJ Res Inst Chem, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan
[2] Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan
[3] Virginia State Univ, Food Chem & Nutr Sci Res Lab, Petersburg, VA USA
[4] Univ Mohammed Premier, Fac Sci, Lab Chim Materiaux, Oujda 60000, Morocco
关键词
Anti-inflammatory; Anti-lymphoma; Nyctanthesin A; B; -Cells; Non -Hodgkin lymphoma; PHENYLETHANOID GLYCOSIDES; CANCER; ASSAY; PROLIFERATION; GROWTH; LEAVES;
D O I
10.1016/j.jep.2022.115267
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Nyctanthes arbor-tristis Linn. is native to Indo-Pak sub-continent and has high medicinal values in Ayureda. This plant has been used traditionally for the treatment of sciatica, rheumatism, chronic fever, diabetes, snakebite, dysentery, cachexia and cancer. Studies have shown many pharmacological properties such as anti-cancer efficacy against Dalton's ascetic lymphoma, cytotoxicity against T-cell leukemia, anti-inflammatory, anti-diabetic and anti-oxidant effects. Aim of the study:Aim of the study was to explore the anti-inflammatory and anti-proliferative potential of N. arbor-tristis.Material and methods: Ethanol extract of fresh and uncrushed aerial parts of N. arbor-tristis was used in the present study. A new compound nyctanthesin A was isolated following a bioactivity-guided fractionation and chro-matographic separations. Its chemical structure was elucidated through spectral studies including 1D, 2D-NMR experiments and HREIMS. The intracellular reactive oxygen species (ROS) and nitric oxide (NO) generation from phagocytes were detected by chemiluminescence technique and Griess method, respectively. TNF-alpha and TGF-fi production was quantified by ELISA. Anti-lymphoma and cytotoxic activities were assessed by alamar blue and MTT assays, respectively. The transcription and protein expression level of Bcl-2, COX-2, p38 MAPK, PDL-1, NF-Kappa B, c-Myc and PNF-Kappa B was performed by qRT-PCR and protein blot assays, respectively.Results: Petroleum ether insoluble fraction of the ethanol extract of fresh and uncrushed aerial parts of N. arbor-tristis revealed anti-inflammatory potential by inhibiting ROS. A previously undescribed compound nyctanthesin A was isolated from this fraction and characterized by UV, IR, NMR and HREIMS. It showed significant anti-inflammatory property by inhibiting ROS, NO and TNF-alpha production. The strong anti-proliferative effects on B-cell lymphoma cells, DOHH2 and Raji, revealed its anti-lymphoma potential along with non-toxic profile against BJ and NIH-3T3 fibroblast cells of normal origin. The qRT-PCR results showed marked inhibition of Bcl-2, COX-2, p38 MAPK, PDL-1, c-Myc, NF-Kappa B, and PNF-Kappa B at transcription level in DOHH2 cells with comparatively lesser but significant effects in Raji cells, where the expression of Bcl-2 gene was not affected. The protein expression of PNF-Kappa B in DOHH2 cells was inhibited by 66% (P < 0.05) and COX-2 in both cell lines was inhibited by 50% (P < 0.05) at 60 mu g/mL. A moderate non-significant inhibition of TGF-fi (~20%) was observed in both cell lines at 100 mu g/mL Conclusions: Scientific evidences reported here validate the anti-inflammatory and anti-cancer potential of the plant.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Anti-inflammatory and urease inhibitory iridoid glycosides from Nyctanthes arbor-tristis Linn.
    Sana, Talea
    Khan, Majid
    Siddiqui, Bina S.
    Baig, Tariq Ahmad
    Jabeen, Almas
    Begum, Sabira
    Hadda, Taibi B.
    Shah, Luqman
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 319
  • [2] Analgesic and Anti-Inflammatory Activities of the Methanolic Stem Bark Extract of Nyctanthes arbor-tristis Linn.
    Kakoti, Bibhuti Bhusan
    Pradhan, Paresh
    Borah, Sudarshana
    Mahato, Kabita
    Kumar, Mritunjay
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [3] Computational Molecular Docking and Simulation-Based Assessment of Anti-Inflammatory Properties of Nyctanthes arbor-tristis Linn Phytochemicals
    Ahmad, Varish
    Khan, Mohammad Imran
    Jamal, Qazi Mohammad Sajid
    Alzahrani, Faisal A.
    Albiheyri, Raed
    PHARMACEUTICALS, 2024, 17 (01)
  • [4] Isolation and characterization of an iridoid, Arbortristoside-C from Nyctanthes arbor-tristis Linn., a potential drug candidate for diabetes targeting α-glucosidase
    Vajravijayan, S.
    Nandhagopal, N.
    Anantha Krishnan, D.
    Gunasekaran, K.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (01): : 337 - 347
  • [5] Oxadiazole Derivatives of Diclofenac as an Anti-proliferative Agent for B-cell Non-Hodgkin Lymphoma: An In vitro and In Silico Studies
    Qayyum, Shaista
    Jabeen, Almas
    Ashraf, Sajda
    Seraj, Faiza
    Khan, Khalid Mohammad
    Siddiqui, Rafat Ali
    Ul-Haq, Zaheer
    MEDICINAL CHEMISTRY, 2024, 20 (04) : 443 - 451
  • [6] Antiproliferative Activity and Characterization of Metabolites of Aspergillus nidulans: An Endophytic Fungus from Nyctanthes arbor-tristis Linn. Against Three Human Cancer Cell Lines
    Sana, Talea
    Siddiqui, Bina S.
    Shahzad, Saleem
    Farooq, Ahsana D.
    Siddiqui, Faheema
    Sattar, Samia
    Begum, Sabira
    MEDICINAL CHEMISTRY, 2019, 15 (04) : 352 - 359
  • [7] Abortitristoside A and desrhamnosylverbanscoside: the potential COX-2 inhibitor from the leaves of Nyctanthes arbor-tristis as anti-inflammatory agents based on the in vitro assay, molecular docking and ADMET prediction
    Rahul Kumar Vishwakarma
    Devendra Singh Negi
    Aaysha Negi
    Chemical Papers, 2023, 77 : 3035 - 3049
  • [8] Abortitristoside A and desrhamnosylverbanscoside: the potential COX-2 inhibitor from the leaves of Nyctanthes arbor-tristis as anti-inflammatory agents based on the in vitro assay, molecular docking and ADMET prediction
    Vishwakarma, Rahul Kumar
    Negi, Devendra Singh
    Negi, Aaysha
    CHEMICAL PAPERS, 2023, 77 (06) : 3035 - 3049
  • [9] Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma
    Abramson, Jeremy S.
    TRANSFUSION MEDICINE REVIEWS, 2020, 34 (01) : 29 - 33
  • [10] Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
    Sacchi, S
    Federico, M
    Dastoli, G
    Fiorani, C
    Vinci, G
    Clò, V
    Casolari, B
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) : 13 - 25